0.5% Ivermectin Cream
DrugUp to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
NCT Number: NCT01068158
The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.
Looking for future studies?
Notify Me5 month and older
All sexes
Interventional
Phase 3
Arkansas Pediatric Clinic, Little Rock, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
up to 4 ounces of topical vehicle control to head and scalp on day 1.
Time frame: Day 2 up to Day 15 post-application
Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Adverse events were defined and classified as follows:
'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
Time frame: Day 2 up to Day 15 post-application
Severe skin/scalp irritations were defined as follows:
Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
Topaz Pharmaceuticals Inc
Industry
A Double-Blind Randomized Study to Compare the Efficacy, Safety, and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation
Acronym: LICE OUT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05565820
Ectoparasitic Infestations, Head Lice
Miami, Florida, United States
View Trial DetailsNCT06333054
Head Lice
Erfurt, Germany
View Trial DetailsNCT02974088
Ectoparasitic Infestations, Head Lice
Cambridge, United Kingdom
View Trial DetailsNCT03617926
Head Lice, Pediculosis Capitis
Miami, Florida, United States
View Trial Details